Related references
Note: Only part of the references are listed.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells
Jacqueline E. Noll et al.
HAEMATOLOGICA (2014)
Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength
Greg C. Smith et al.
FEBS JOURNAL (2013)
Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1
Jessica A. Fowler et al.
CANCER RESEARCH (2012)
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
Stephen Fitter et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2012)
Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations
J. Glassford et al.
BLOOD CANCER JOURNAL (2012)
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
J. E. Noll et al.
BLOOD CANCER JOURNAL (2012)
NVP-BEZ235, A Dual Pan Class I PI3 Kinase and mTOR Inhibitor, Promotes Osteogenic Differentiation in Human Mesenchymal Stromal Cells
Sally K. Martin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The Tyrosine Kinase Inhibitor Dasatinib Dysregulates Bone Remodeling Through Inhibition of Osteoclasts In Vivo
Kate Vandyke et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Rapamycin Promotes the Osteoblastic Differentiation of Human Embryonic Stem Cells by Blocking the mTOR Pathway and Stimulating the BMP/Smad Pathway
Kyu-Won Lee et al.
STEM CELLS AND DEVELOPMENT (2010)
Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
Douglas W. McMillin et al.
CANCER RESEARCH (2009)
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
Philipp Baumann et al.
EXPERIMENTAL CELL RESEARCH (2009)
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Romina Marone et al.
MOLECULAR CANCER RESEARCH (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter et al.
BLOOD (2008)
Exploring the specificity of the PI3K family inhibitor LY294002
Severine I. Gharbi et al.
BIOCHEMICAL JOURNAL (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
An expanding role for mTOR in cancer
DA Guertin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation
I Kratchmarova et al.
SCIENCE (2005)
Akt1/Akt2 and mammalian target of rapamycin/bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors
T Sugatani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
JW Lee et al.
BLOOD (2004)
Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor α myeloma cells
S Abroun et al.
BLOOD (2004)
Differential growth factor control of bone formation through osteoprogenitor differentiation
LR Chaudhary et al.
BONE (2004)
Targeting the PI3K-Akt pathway in human cancer: Rationale and promise
J Luo et al.
CANCER CELL (2003)
M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase
H Glantschnig et al.
CELL DEATH AND DIFFERENTIATION (2003)
Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
BO Oyajobi et al.
BLOOD (2003)
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival
A Gingery et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM
S Uneda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma
F Pene et al.
ONCOGENE (2002)
Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor
K Kubota et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2
F Viñals et al.
FEBS LETTERS (2002)
The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation
SE Lee et al.
BONE (2002)
Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma
T Hideshima et al.
ONCOGENE (2001)
Share Paper
